[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

European Pap Smear/HPV Market 2015

April 2015 | 235 pages | ID: E4840492301EN
Venture Planning Group

US$ 2,280.00 US$ 2,850.00 -20 %

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Complete report $2,850. DataPack (test volumes, sales forecasts) $1,850.This report presents a detailed analysis of the Pap Smear/HPV testing market in Europe (France, Germany, Italy, Spain, UK), including clinical significance and current laboratory practice; as well as five-year test volume and sales forecasts by country and market segment. The report examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.Contains 235 pages and 11 tables
I. INTRODUCTION

II. PAP SMEAR/HPV @WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Pap Smear/HPV: Clinical Significance and Laboratory Practices B. Current and Emerging Technologies
  1. Monoclonal and Polyclonal Antibodies
  2. Immunoassays
    a. Technological Principle
    b. Radioimmunoassay (RIA)
    c. Enzyme Immunoassays (EIA)
      Overview
    ELISA
    Immunofiltration
    Particle-Membrane Capture Immunoassay
    Enzyme Amplification
    d. Fluorescent Immunoassays
    e. Luminescence
    Chemiluminescence
    Bioluminescence
    f. Latex Agglutination
    g. Immunoprecipitation
H. Affinity Chromatographu
    e. Liposome Flow-Injection Immunoassay
  3. Molecular Diagnostics
    a. Technology Overview
    b. Amplification Methods
    PCR
    DAP-PCR
    Immuno-PCR
    QC-PCR
      CAR
    DNA
    HPA
    LCR
    NASBA
    QBR
    SDA
    3 SR, and others
  4. Chromosome Analysis
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. Artificial Intelligence
  6. Flow Cytometry
  7. Two Dimensional Gel Electrophoresis (2-DGE)
  8. Biosensors
  9. Competing/Complementing Technologies
    a. CT
    b. MRI
    c. NMR
    d. PET
    e. Photonics Spectroscopy
C. Personal Testing

FRANCE: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT

GERMANY: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT

ITALY: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT

SPAIN: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT

U.K.: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT

III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

IV. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
  1. Marketing Approaches
  2. Product Complexity
  3. Customer Preference
  4. Established Suppliers
  5. Emerging Suppliers
  6. Major Types of Distributors
  7. Market Segmentation Factor

V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VI. CANCER DIAGNOSTIC PRODUCT SUPPLIERS

Abbott
AdnaGen
Agilent Technologies
Applied Gene Technologies
Arca/Nuvelo
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid
Correlogic Systems/Vermillion
Decode
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Epigenomics
Enterix
Enzo Biochem
Exact Sciences
Fujirebio/Innogenetics
Guided Therapeutics
Hologic/Gen-Probe
Kreatech
Kyowa Medex
Life Technologies
Mackay Life Sciences
Myriad Genetics
Nanogen Elitech
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen/Ipsogen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

LIST OF TABLES

Major Companies Developing or Marketing Pap Smear/HPV Tests
France Pap Smear Test Volume and Diagnostics Sales by Market Segment
France Papillomavirus (HPV) Test Volume and Diagnostics Sales Forecast by Market Segment
Germany Pap Smear Test Volume and Diagnostics Sales by Market Segment
Germany Papillomavirus(HPV) Test Volume and Diagnostics Sales Forecast by Market Segment
Italy Pap Smear Test Volume and Diagnostics Sales by Market Segment
Italy Papillomavirus(HPV) Test Volume and Diagnostics Sales Forecast by Market Segment
Spain Pap Smear Test Volume and Diagnostics Sales by Market Segment
Spain Papillomavirus (HPV) Test Volume and Diagnostics Sales Forecast by Market Segment
U.K. Pap Smear Test Volume and Diagnostics Sales by Market Segment
U.K. Papillomavirus(HPV) Test Volume and Diagnostics Sales Forecast by Market Segment


More Publications